Metabolite Tales Blog

JULY 5, 2023

Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. Current macrocycles in clinical use generally focus on treatment of infectious diseases, cancer and auto-immune disorders. Nagasaka et al.,

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

Metabolite Tales Blog

JULY 5, 2023

Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. Current macrocycles in clinical use generally focus on treatment of infectious diseases, cancer and auto-immune disorders. Nagasaka et al.,

Metabolic Stability 52

Metabolic Stability Drugs FDA Approval Treatment 52

Agency IQ

SEPTEMBER 15, 2023

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. FDA’s cough cold monograph only designates two oral products as GRASE – phenylephrine and pseudoephedrine.

Science 40

Science FDA Clinical Trials Clinical Pharmacology 40

New Drug Approvals

APRIL 18, 2025

1] [2] [3] Iomeprol was approved for medical use in the United States in November 2024. [1] in ARKIVOC, 2006, 104 and Tetrahedron Lett., Article ] Rosati G: Clinical pharmacology of iomeprol. 2005, 46, 7179.In g, 50 mmol) was suspended in ethanol (30 mL). Invest Radiol. 2001 Feb;36(2):87-96. Eur J Radiol.

FDA 52

FDA Production FDA Approval Clinical Pharmacology 52